Home
Search Center
Journal List
CMA
Contact US
|
Chinese
You Position:
Home
> Paper
Progression of biological reagent therapy for ankylosing spondylitis
( views:463, downloads:84 )
Author:
No author available
Journal Title:
JOURNAL OF MODERN CLINICAL MEDICAL BIOENGINEERING
Issue:
6
DOI:
10.3760/cma.j.issn.1008-634X.2006.06.001
Key Word:
No keyword available
Abstract: @@ 近年来国内外在风湿免疫性疾病的生物制剂治疗的基础与临床方面已展开了广泛的研究和讨论.生物制剂作为最新的有效治疗策略使该类疾病治疗方法发生了巨大的变化,水平得到了极大提高.
Reference
[1]Wallace MR,Lederman ER,Crum NF.
Infections associated with tumor necrosis factor-alpha antagonists.
[J].2005,84(5).
[2]C, Antoni,J, Braun.
Side effects of anti-TNF therapy: current knowledge.
[J].1900,20(6 Suppl 28).
[3]Davis JC Jr,Gorman JD,Sack KE.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
[J].2002,346(18).
[4]Brandt J,Braun J,Haibel H,etc.
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
[J].2002,29(1).
[5]Braun J,Listing J,Schneider M,etc.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
[J].2002,359(9313).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData
|
Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:
yiyao@wanfangdata.com.cn